These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28710059)

  • 1. A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
    Lin S; Ptasinska A; Chen X; Shrestha M; Assi SA; Chin PS; Imperato MR; Aronow BJ; Zhang J; Weirauch MT; Bonifer C; Mulloy JC
    Blood; 2017 Sep; 130(10):1213-1222. PubMed ID: 28710059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.
    Chou FS; Griesinger A; Wunderlich M; Lin S; Link KA; Shrestha M; Goyama S; Mizukawa B; Shen S; Marcucci G; Mulloy JC
    Blood; 2012 Jul; 120(4):709-19. PubMed ID: 22337712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition of a small core transcriptional circuit regulated by AML1-ETO.
    Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
    Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
    Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
    Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
    Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
    Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
    Schnoeder TM; Schwarzer A; Jayavelu AK; Hsu CJ; Kirkpatrick J; Döhner K; Perner F; Eifert T; Huber N; Arreba-Tutusaus P; Dolnik A; Assi SA; Nafria M; Jiang L; Dai YT; Chen Z; Chen SJ; Kellaway SG; Ptasinska A; Ng ES; Stanley EG; Elefanty AG; Buschbeck M; Bierhoff H; Brodt S; Matziolis G; Fischer KD; Hochhaus A; Chen CW; Heidenreich O; Mann M; Lane SW; Bullinger L; Ori A; von Eyss B; Bonifer C; Heidel FH
    Blood; 2022 Feb; 139(7):1080-1097. PubMed ID: 34695195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
    Zhang Y; Wang J; Wheat J; Chen X; Jin S; Sadrzadeh H; Fathi AT; Peterson RT; Kung AL; Sweetser DA; Yeh JR
    Blood; 2013 Jun; 121(24):4906-16. PubMed ID: 23645839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
    Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
    PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
    Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
    BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.
    Di Genua C; Norfo R; Rodriguez-Meira A; Wen WX; Drissen R; Booth CAG; Povinelli B; Repapi E; Gray N; Carrelha J; Kettyle LM; Jamieson L; Neo WH; Thongjuea S; Nerlov C; Mead AJ
    Haematologica; 2019 Nov; 104(11):2215-2224. PubMed ID: 30975913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
    Xu Y; Man N; Karl D; Martinez C; Liu F; Sun J; Martinez CJ; Martin GM; Beckedorff F; Lai F; Yue J; Roisman A; Greenblatt S; Duffort S; Wang L; Sun X; Figueroa M; Shiekhattar R; Nimer S
    Nat Commun; 2019 Oct; 10(1):4925. PubMed ID: 31664040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
    Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
    Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
    Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
    Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
    Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L
    Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
    Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
    Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
    Martens JH; Mandoli A; Simmer F; Wierenga BJ; Saeed S; Singh AA; Altucci L; Vellenga E; Stunnenberg HG
    Blood; 2012 Nov; 120(19):4038-48. PubMed ID: 22983443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting miR-193a-AML1-ETO-β-catenin axis by melatonin suppresses the self-renewal of leukaemia stem cells in leukaemia with t (8;21) translocation.
    Zhou B; Ye H; Xing C; Liang B; Li H; Chen L; Huang X; Wu Y; Gao S
    J Cell Mol Med; 2019 Aug; 23(8):5246-5258. PubMed ID: 31119862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.
    Wang L; Gural A; Sun XJ; Zhao X; Perna F; Huang G; Hatlen MA; Vu L; Liu F; Xu H; Asai T; Xu H; Deblasio T; Menendez S; Voza F; Jiang Y; Cole PA; Zhang J; Melnick A; Roeder RG; Nimer SD
    Science; 2011 Aug; 333(6043):765-9. PubMed ID: 21764752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.